【 中文摘要 】血管緊張素II(血管緊張素II)與高血壓及其并發症密切相關。 證據提示血管緊張素II(血管緊張素II)升高血壓和增強心血管重構和損傷的機制可能是明顯的。 在血管平滑肌細胞中，金屬蛋白酶ADAM17介導表皮生長因子受體(EGER)反式激活，其可能負責心血管重構，但不負責血管II誘導的高血壓。 用人交叉反應性ADAM17抑制抗體(A9B8)治療也可預防灌注血管II的C57BL/6小鼠的心血管，重構和ER應激而不是高血壓。 體外數據進一步支持這些發現。 總之，血管ADAM17通過EGFR激活介導血管誘導的心血管重構，而與血壓調節無關。 ADAM17爲抗體如A9B8提供了獨特的治療靶點，用于預防高血壓并發症。

【 英文摘要 】Angiotensin II (AngII) has been strongly implicated in hypertension and its complications. Evidence suggests the mechanisms by which angiotensin II (AngII) elevates blood pressure and enhances cardiovascular remodeling and damage may be distinct. In vascular smooth muscle cells, a metaloproteinase ADAM17 mediates epidermal growth factor receptor (EGER) transactivation, which may be responsible for cardiovascular remodeling but not hypertension induced by AngII. Treatment with a human cross-reactive ADAM17 inhibitory antibody (A9B8) also prevented cardiovascular, remodeling and ER stress but not hypertension in C57Bl/6 mice infused with AngII. In vitro data further supported these findings. In conclusion, vascular ADAM17 mediates AngII-induced cardiovascular remodeling via EGFR activation independent of blood pressure regulation. ADAM17 presents a unique therapeutic target for antibodies such as A9B8 for the prevention of hypertensive complications.

[ 英文標題 ]

【 技術功效 】

【技術分類】

【行業分類】

【 首項權利要求-原文 】

1. A method of treating cardiovascular hypertrophy induced by angiotensin II which comprises suppressing ADAM 17 activity by administering a therapeutic dose of antibody A9B8 to a subject in need thereof.

【 首項權利要求-翻譯 】

1. 一種治療由血管緊張素II誘導的心血管肥大的方法，該方法包括通過給予需要治療劑量的抗體A9B8來抑制ADAM17活性。